New York, April 19, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Vaginitis Therapeutics Industry" - https://www.reportlinker.com/p06033213/?utm_source=GNW
7 Billion in the year 2020, is projected to reach a revised size of US$4.4 Billion by 2027, growing at a CAGR of 7.1% over the analysis period 2020-2027. Anti-Bacterial, one of the segments analyzed in the report, is projected to record a 6.9% CAGR and reach US$1.8 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Anti-Fungal segment is readjusted to a revised 7.2% CAGR for the next 7-year period.
- The U.S. Market is Estimated at $735 Million, While China is Forecast to Grow at 10.8% CAGR
- The Vaginitis Therapeutics market in the U.S. is estimated at US$735 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$965.9 Million by the year 2027 trailing a CAGR of 10.8% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.9% and 6.4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.6% CAGR.
- Hormone Segment to Record 7.4% CAGR
- In the global Hormone segment, USA, Canada, Japan, China and Europe will drive the 6.8% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$428.8 Million in the year 2020 will reach a projected size of US$680.5 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$604 Million by the year 2027, while Latin America will expand at a 8.8% CAGR through the analysis period.
- Select Competitors (Total 42 Featured) -
- Bayer AG
- Janssen Pharmaceuticals Inc.
- Lumavita AG
- Lupin Pharmaceuticals Inc.
- Merck & Co., Inc.
- Mission Pharmacal Company
- Novartis AG
- Pfizer Inc.
- Symbiomix Therapeutics LLC
- Teva Pharmaceutical Industries Ltd
Read the full report: https://www.reportlinker.com/p06033213/?utm_source=GNW
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Vaginitis
Therapeutics by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR
Table 2: World Historic Review for Vaginitis Therapeutics by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 3: World 15-Year Perspective for Vaginitis Therapeutics
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets for Years 2012, 2020 & 2027
Table 4: World Current & Future Analysis for Anti-Bacterial by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR
Table 5: World Historic Review for Anti-Bacterial by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR
Table 6: World 15-Year Perspective for Anti-Bacterial by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027
Table 7: World Current & Future Analysis for Anti-Fungal by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR
Table 8: World Historic Review for Anti-Fungal by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR
Table 9: World 15-Year Perspective for Anti-Fungal by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027
Table 10: World Current & Future Analysis for Hormone by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR
Table 11: World Historic Review for Hormone by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR
Table 12: World 15-Year Perspective for Hormone by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2020 & 2027
Table 13: World Current & Future Analysis for Prescription (Rx)
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR
Table 14: World Historic Review for Prescription (Rx) by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 15: World 15-Year Perspective for Prescription (Rx) by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027
Table 16: World Current & Future Analysis for Over-the-Counter
(OTC) by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR
Table 17: World Historic Review for Over-the-Counter (OTC) by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 18: World 15-Year Perspective for Over-the-Counter (OTC)
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027
III. MARKET ANALYSIS
UNITED STATES
Table 19: USA Current & Future Analysis for Vaginitis
Therapeutics by Product - Anti-Bacterial, Anti-Fungal and
Hormone - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR
Table 20: USA Historic Review for Vaginitis Therapeutics by
Product - Anti-Bacterial, Anti-Fungal and Hormone Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 21: USA 15-Year Perspective for Vaginitis Therapeutics by
Product - Percentage Breakdown of Value Sales for
Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012,
2020 & 2027
Table 22: USA Current & Future Analysis for Vaginitis
Therapeutics by Type - Prescription (Rx) and Over-the-Counter
(OTC) - Independent Analysis of Annual Sales in US$ Million for
the Years 2020 through 2027 and % CAGR
Table 23: USA Historic Review for Vaginitis Therapeutics by
Type - Prescription (Rx) and Over-the-Counter (OTC) Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 24: USA 15-Year Perspective for Vaginitis Therapeutics by
Type - Percentage Breakdown of Value Sales for Prescription
(Rx) and Over-the-Counter (OTC) for the Years 2012, 2020 & 2027
CANADA
Table 25: Canada Current & Future Analysis for Vaginitis
Therapeutics by Product - Anti-Bacterial, Anti-Fungal and
Hormone - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR
Table 26: Canada Historic Review for Vaginitis Therapeutics by
Product - Anti-Bacterial, Anti-Fungal and Hormone Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 27: Canada 15-Year Perspective for Vaginitis Therapeutics
by Product - Percentage Breakdown of Value Sales for
Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012,
2020 & 2027
Table 28: Canada Current & Future Analysis for Vaginitis
Therapeutics by Type - Prescription (Rx) and Over-the-Counter
(OTC) - Independent Analysis of Annual Sales in US$ Million for
the Years 2020 through 2027 and % CAGR
Table 29: Canada Historic Review for Vaginitis Therapeutics by
Type - Prescription (Rx) and Over-the-Counter (OTC) Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 30: Canada 15-Year Perspective for Vaginitis Therapeutics
by Type - Percentage Breakdown of Value Sales for Prescription
(Rx) and Over-the-Counter (OTC) for the Years 2012, 2020 & 2027
JAPAN
Table 31: Japan Current & Future Analysis for Vaginitis
Therapeutics by Product - Anti-Bacterial, Anti-Fungal and
Hormone - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR
Table 32: Japan Historic Review for Vaginitis Therapeutics by
Product - Anti-Bacterial, Anti-Fungal and Hormone Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 33: Japan 15-Year Perspective for Vaginitis Therapeutics
by Product - Percentage Breakdown of Value Sales for
Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012,
2020 & 2027
Table 34: Japan Current & Future Analysis for Vaginitis
Therapeutics by Type - Prescription (Rx) and Over-the-Counter
(OTC) - Independent Analysis of Annual Sales in US$ Million for
the Years 2020 through 2027 and % CAGR
Table 35: Japan Historic Review for Vaginitis Therapeutics by
Type - Prescription (Rx) and Over-the-Counter (OTC) Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 36: Japan 15-Year Perspective for Vaginitis Therapeutics
by Type - Percentage Breakdown of Value Sales for Prescription
(Rx) and Over-the-Counter (OTC) for the Years 2012, 2020 & 2027
CHINA
Table 37: China Current & Future Analysis for Vaginitis
Therapeutics by Product - Anti-Bacterial, Anti-Fungal and
Hormone - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR
Table 38: China Historic Review for Vaginitis Therapeutics by
Product - Anti-Bacterial, Anti-Fungal and Hormone Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 39: China 15-Year Perspective for Vaginitis Therapeutics
by Product - Percentage Breakdown of Value Sales for
Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012,
2020 & 2027
Table 40: China Current & Future Analysis for Vaginitis
Therapeutics by Type - Prescription (Rx) and Over-the-Counter
(OTC) - Independent Analysis of Annual Sales in US$ Million for
the Years 2020 through 2027 and % CAGR
Table 41: China Historic Review for Vaginitis Therapeutics by
Type - Prescription (Rx) and Over-the-Counter (OTC) Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 42: China 15-Year Perspective for Vaginitis Therapeutics
by Type - Percentage Breakdown of Value Sales for Prescription
(Rx) and Over-the-Counter (OTC) for the Years 2012, 2020 & 2027
EUROPE
Table 43: Europe Current & Future Analysis for Vaginitis
Therapeutics by Geographic Region - France, Germany, Italy, UK,
Spain, Russia and Rest of Europe Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 and
% CAGR
Table 44: Europe Historic Review for Vaginitis Therapeutics by
Geographic Region - France, Germany, Italy, UK, Spain, Russia
and Rest of Europe Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 45: Europe 15-Year Perspective for Vaginitis Therapeutics
by Geographic Region - Percentage Breakdown of Value Sales for
France, Germany, Italy, UK, Spain, Russia and Rest of Europe
Markets for Years 2012, 2020 & 2027
Table 46: Europe Current & Future Analysis for Vaginitis
Therapeutics by Product - Anti-Bacterial, Anti-Fungal and
Hormone - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR
Table 47: Europe Historic Review for Vaginitis Therapeutics by
Product - Anti-Bacterial, Anti-Fungal and Hormone Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 48: Europe 15-Year Perspective for Vaginitis Therapeutics
by Product - Percentage Breakdown of Value Sales for
Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012,
2020 & 2027
Table 49: Europe Current & Future Analysis for Vaginitis
Therapeutics by Type - Prescription (Rx) and Over-the-Counter
(OTC) - Independent Analysis of Annual Sales in US$ Million for
the Years 2020 through 2027 and % CAGR
Table 50: Europe Historic Review for Vaginitis Therapeutics by
Type - Prescription (Rx) and Over-the-Counter (OTC) Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 51: Europe 15-Year Perspective for Vaginitis Therapeutics
by Type - Percentage Breakdown of Value Sales for Prescription
(Rx) and Over-the-Counter (OTC) for the Years 2012, 2020 & 2027
FRANCE
Table 52: France Current & Future Analysis for Vaginitis
Therapeutics by Product - Anti-Bacterial, Anti-Fungal and
Hormone - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR
Table 53: France Historic Review for Vaginitis Therapeutics by
Product - Anti-Bacterial, Anti-Fungal and Hormone Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 54: France 15-Year Perspective for Vaginitis Therapeutics
by Product - Percentage Breakdown of Value Sales for
Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012,
2020 & 2027
Table 55: France Current & Future Analysis for Vaginitis
Therapeutics by Type - Prescription (Rx) and Over-the-Counter
(OTC) - Independent Analysis of Annual Sales in US$ Million for
the Years 2020 through 2027 and % CAGR
Table 56: France Historic Review for Vaginitis Therapeutics by
Type - Prescription (Rx) and Over-the-Counter (OTC) Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 57: France 15-Year Perspective for Vaginitis Therapeutics
by Type - Percentage Breakdown of Value Sales for Prescription
(Rx) and Over-the-Counter (OTC) for the Years 2012, 2020 & 2027
GERMANY
Table 58: Germany Current & Future Analysis for Vaginitis
Therapeutics by Product - Anti-Bacterial, Anti-Fungal and
Hormone - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR
Table 59: Germany Historic Review for Vaginitis Therapeutics by
Product - Anti-Bacterial, Anti-Fungal and Hormone Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 60: Germany 15-Year Perspective for Vaginitis
Therapeutics by Product - Percentage Breakdown of Value Sales
for Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012,
2020 & 2027
Table 61: Germany Current & Future Analysis for Vaginitis
Therapeutics by Type - Prescription (Rx) and Over-the-Counter
(OTC) - Independent Analysis of Annual Sales in US$ Million for
the Years 2020 through 2027 and % CAGR
Table 62: Germany Historic Review for Vaginitis Therapeutics by
Type - Prescription (Rx) and Over-the-Counter (OTC) Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 63: Germany 15-Year Perspective for Vaginitis
Therapeutics by Type - Percentage Breakdown of Value Sales for
Prescription (Rx) and Over-the-Counter (OTC) for the Years
2012, 2020 & 2027
ITALY
Table 64: Italy Current & Future Analysis for Vaginitis
Therapeutics by Product - Anti-Bacterial, Anti-Fungal and
Hormone - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR
Table 65: Italy Historic Review for Vaginitis Therapeutics by
Product - Anti-Bacterial, Anti-Fungal and Hormone Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 66: Italy 15-Year Perspective for Vaginitis Therapeutics
by Product - Percentage Breakdown of Value Sales for
Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012,
2020 & 2027
Table 67: Italy Current & Future Analysis for Vaginitis
Therapeutics by Type - Prescription (Rx) and Over-the-Counter
(OTC) - Independent Analysis of Annual Sales in US$ Million for
the Years 2020 through 2027 and % CAGR
Table 68: Italy Historic Review for Vaginitis Therapeutics by
Type - Prescription (Rx) and Over-the-Counter (OTC) Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 69: Italy 15-Year Perspective for Vaginitis Therapeutics
by Type - Percentage Breakdown of Value Sales for Prescription
(Rx) and Over-the-Counter (OTC) for the Years 2012, 2020 & 2027
UNITED KINGDOM
Table 70: UK Current & Future Analysis for Vaginitis
Therapeutics by Product - Anti-Bacterial, Anti-Fungal and
Hormone - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR
Table 71: UK Historic Review for Vaginitis Therapeutics by
Product - Anti-Bacterial, Anti-Fungal and Hormone Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 72: UK 15-Year Perspective for Vaginitis Therapeutics by
Product - Percentage Breakdown of Value Sales for
Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012,
2020 & 2027
Table 73: UK Current & Future Analysis for Vaginitis
Therapeutics by Type - Prescription (Rx) and Over-the-Counter
(OTC) - Independent Analysis of Annual Sales in US$ Million for
the Years 2020 through 2027 and % CAGR
Table 74: UK Historic Review for Vaginitis Therapeutics by Type -
Prescription (Rx) and Over-the-Counter (OTC) Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 75: UK 15-Year Perspective for Vaginitis Therapeutics by
Type - Percentage Breakdown of Value Sales for Prescription
(Rx) and Over-the-Counter (OTC) for the Years 2012, 2020 & 2027
SPAIN
Table 76: Spain Current & Future Analysis for Vaginitis
Therapeutics by Product - Anti-Bacterial, Anti-Fungal and
Hormone - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR
Table 77: Spain Historic Review for Vaginitis Therapeutics by
Product - Anti-Bacterial, Anti-Fungal and Hormone Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 78: Spain 15-Year Perspective for Vaginitis Therapeutics
by Product - Percentage Breakdown of Value Sales for
Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012,
2020 & 2027
Table 79: Spain Current & Future Analysis for Vaginitis
Therapeutics by Type - Prescription (Rx) and Over-the-Counter
(OTC) - Independent Analysis of Annual Sales in US$ Million for
the Years 2020 through 2027 and % CAGR
Table 80: Spain Historic Review for Vaginitis Therapeutics by
Type - Prescription (Rx) and Over-the-Counter (OTC) Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 81: Spain 15-Year Perspective for Vaginitis Therapeutics
by Type - Percentage Breakdown of Value Sales for Prescription
(Rx) and Over-the-Counter (OTC) for the Years 2012, 2020 & 2027
RUSSIA
Table 82: Russia Current & Future Analysis for Vaginitis
Therapeutics by Product - Anti-Bacterial, Anti-Fungal and
Hormone - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR
Table 83: Russia Historic Review for Vaginitis Therapeutics by
Product - Anti-Bacterial, Anti-Fungal and Hormone Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 84: Russia 15-Year Perspective for Vaginitis Therapeutics
by Product - Percentage Breakdown of Value Sales for
Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012,
2020 & 2027
Table 85: Russia Current & Future Analysis for Vaginitis
Therapeutics by Type - Prescription (Rx) and Over-the-Counter
(OTC) - Independent Analysis of Annual Sales in US$ Million for
the Years 2020 through 2027 and % CAGR
Table 86: Russia Historic Review for Vaginitis Therapeutics by
Type - Prescription (Rx) and Over-the-Counter (OTC) Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 87: Russia 15-Year Perspective for Vaginitis Therapeutics
by Type - Percentage Breakdown of Value Sales for Prescription
(Rx) and Over-the-Counter (OTC) for the Years 2012, 2020 & 2027
REST OF EUROPE
Table 88: Rest of Europe Current & Future Analysis for
Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal
and Hormone - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR
Table 89: Rest of Europe Historic Review for Vaginitis
Therapeutics by Product - Anti-Bacterial, Anti-Fungal and
Hormone Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR
Table 90: Rest of Europe 15-Year Perspective for Vaginitis
Therapeutics by Product - Percentage Breakdown of Value Sales
for Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012,
2020 & 2027
Table 91: Rest of Europe Current & Future Analysis for
Vaginitis Therapeutics by Type - Prescription (Rx) and
Over-the-Counter (OTC) - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR
Table 92: Rest of Europe Historic Review for Vaginitis
Therapeutics by Type - Prescription (Rx) and Over-the-Counter
(OTC) Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR
Table 93: Rest of Europe 15-Year Perspective for Vaginitis
Therapeutics by Type - Percentage Breakdown of Value Sales for
Prescription (Rx) and Over-the-Counter (OTC) for the Years
2012, 2020 & 2027
ASIA-PACIFIC
Table 94: Asia-Pacific Current & Future Analysis for Vaginitis
Therapeutics by Geographic Region - Australia, India, South
Korea and Rest of Asia-Pacific Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 and
% CAGR
Table 95: Asia-Pacific Historic Review for Vaginitis
Therapeutics by Geographic Region - Australia, India, South
Korea and Rest of Asia-Pacific Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR
Table 96: Asia-Pacific 15-Year Perspective for Vaginitis
Therapeutics by Geographic Region - Percentage Breakdown of
Value Sales for Australia, India, South Korea and Rest of
Asia-Pacific Markets for Years 2012, 2020 & 2027
Table 97: Asia-Pacific Current & Future Analysis for Vaginitis
Therapeutics by Product - Anti-Bacterial, Anti-Fungal and
Hormone - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR
Table 98: Asia-Pacific Historic Review for Vaginitis
Therapeutics by Product - Anti-Bacterial, Anti-Fungal and
Hormone Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR
Table 99: Asia-Pacific 15-Year Perspective for Vaginitis
Therapeutics by Product - Percentage Breakdown of Value Sales
for Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012,
2020 & 2027
Table 100: Asia-Pacific Current & Future Analysis for Vaginitis
Therapeutics by Type - Prescription (Rx) and Over-the-Counter
(OTC) - Independent Analysis of Annual Sales in US$ Million for
the Years 2020 through 2027 and % CAGR
Table 101: Asia-Pacific Historic Review for Vaginitis
Therapeutics by Type - Prescription (Rx) and Over-the-Counter
(OTC) Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR
Table 102: Asia-Pacific 15-Year Perspective for Vaginitis
Therapeutics by Type - Percentage Breakdown of Value Sales for
Prescription (Rx) and Over-the-Counter (OTC) for the Years
2012, 2020 & 2027
AUSTRALIA
Table 103: Australia Current & Future Analysis for Vaginitis
Therapeutics by Product - Anti-Bacterial, Anti-Fungal and
Hormone - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR
Table 104: Australia Historic Review for Vaginitis Therapeutics
by Product - Anti-Bacterial, Anti-Fungal and Hormone Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 105: Australia 15-Year Perspective for Vaginitis
Therapeutics by Product - Percentage Breakdown of Value Sales
for Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012,
2020 & 2027
Table 106: Australia Current & Future Analysis for Vaginitis
Therapeutics by Type - Prescription (Rx) and Over-the-Counter
(OTC) - Independent Analysis of Annual Sales in US$ Million for
the Years 2020 through 2027 and % CAGR
Table 107: Australia Historic Review for Vaginitis Therapeutics
by Type - Prescription (Rx) and Over-the-Counter (OTC) Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 108: Australia 15-Year Perspective for Vaginitis
Therapeutics by Type - Percentage Breakdown of Value Sales for
Prescription (Rx) and Over-the-Counter (OTC) for the Years
2012, 2020 & 2027
INDIA
Table 109: India Current & Future Analysis for Vaginitis
Therapeutics by Product - Anti-Bacterial, Anti-Fungal and
Hormone - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR
Table 110: India Historic Review for Vaginitis Therapeutics by
Product - Anti-Bacterial, Anti-Fungal and Hormone Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 111: India 15-Year Perspective for Vaginitis Therapeutics
by Product - Percentage Breakdown of Value Sales for
Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012,
2020 & 2027
Table 112: India Current & Future Analysis for Vaginitis
Therapeutics by Type - Prescription (Rx) and Over-the-Counter
(OTC) - Independent Analysis of Annual Sales in US$ Million for
the Years 2020 through 2027 and % CAGR
Table 113: India Historic Review for Vaginitis Therapeutics by
Type - Prescription (Rx) and Over-the-Counter (OTC) Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 114: India 15-Year Perspective for Vaginitis Therapeutics
by Type - Percentage Breakdown of Value Sales for Prescription
(Rx) and Over-the-Counter (OTC) for the Years 2012, 2020 & 2027
SOUTH KOREA
Table 115: South Korea Current & Future Analysis for Vaginitis
Therapeutics by Product - Anti-Bacterial, Anti-Fungal and
Hormone - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR
Table 116: South Korea Historic Review for Vaginitis
Therapeutics by Product - Anti-Bacterial, Anti-Fungal and
Hormone Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR
Table 117: South Korea 15-Year Perspective for Vaginitis
Therapeutics by Product - Percentage Breakdown of Value Sales
for Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012,
2020 & 2027
Table 118: South Korea Current & Future Analysis for Vaginitis
Therapeutics by Type - Prescription (Rx) and Over-the-Counter
(OTC) - Independent Analysis of Annual Sales in US$ Million for
the Years 2020 through 2027 and % CAGR
Table 119: South Korea Historic Review for Vaginitis
Therapeutics by Type - Prescription (Rx) and Over-the-Counter
(OTC) Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR
Table 120: South Korea 15-Year Perspective for Vaginitis
Therapeutics by Type - Percentage Breakdown of Value Sales for
Prescription (Rx) and Over-the-Counter (OTC) for the Years
2012, 2020 & 2027
REST OF ASIA-PACIFIC
Table 121: Rest of Asia-Pacific Current & Future Analysis for
Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal
and Hormone - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR
Table 122: Rest of Asia-Pacific Historic Review for Vaginitis
Therapeutics by Product - Anti-Bacterial, Anti-Fungal and
Hormone Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR
Table 123: Rest of Asia-Pacific 15-Year Perspective for
Vaginitis Therapeutics by Product - Percentage Breakdown of
Value Sales for Anti-Bacterial, Anti-Fungal and Hormone for the
Years 2012, 2020 & 2027
Table 124: Rest of Asia-Pacific Current & Future Analysis for
Vaginitis Therapeutics by Type - Prescription (Rx) and
Over-the-Counter (OTC) - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR
Table 125: Rest of Asia-Pacific Historic Review for Vaginitis
Therapeutics by Type - Prescription (Rx) and Over-the-Counter
(OTC) Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR
Table 126: Rest of Asia-Pacific 15-Year Perspective for
Vaginitis Therapeutics by Type - Percentage Breakdown of Value
Sales for Prescription (Rx) and Over-the-Counter (OTC) for the
Years 2012, 2020 & 2027
LATIN AMERICA
Table 127: Latin America Current & Future Analysis for
Vaginitis Therapeutics by Geographic Region - Argentina,
Brazil, Mexico and Rest of Latin America Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027 and % CAGR
Table 128: Latin America Historic Review for Vaginitis
Therapeutics by Geographic Region - Argentina, Brazil, Mexico
and Rest of Latin America Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR
Table 129: Latin America 15-Year Perspective for Vaginitis
Therapeutics by Geographic Region - Percentage Breakdown of
Value Sales for Argentina, Brazil, Mexico and Rest of Latin
America Markets for Years 2012, 2020 & 2027
Table 130: Latin America Current & Future Analysis for
Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal
and Hormone - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR
Table 131: Latin America Historic Review for Vaginitis
Therapeutics by Product - Anti-Bacterial, Anti-Fungal and
Hormone Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR
Table 132: Latin America 15-Year Perspective for Vaginitis
Therapeutics by Product - Percentage Breakdown of Value Sales
for Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012,
2020 & 2027
Table 133: Latin America Current & Future Analysis for
Vaginitis Therapeutics by Type - Prescription (Rx) and
Over-the-Counter (OTC) - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR
Table 134: Latin America Historic Review for Vaginitis
Therapeutics by Type - Prescription (Rx) and Over-the-Counter
(OTC) Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR
Table 135: Latin America 15-Year Perspective for Vaginitis
Therapeutics by Type - Percentage Breakdown of Value Sales for
Prescription (Rx) and Over-the-Counter (OTC) for the Years
2012, 2020 & 2027
ARGENTINA
Table 136: Argentina Current & Future Analysis for Vaginitis
Therapeutics by Product - Anti-Bacterial, Anti-Fungal and
Hormone - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR
Table 137: Argentina Historic Review for Vaginitis Therapeutics
by Product - Anti-Bacterial, Anti-Fungal and Hormone Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 138: Argentina 15-Year Perspective for Vaginitis
Therapeutics by Product - Percentage Breakdown of Value Sales
for Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012,
2020 & 2027
Table 139: Argentina Current & Future Analysis for Vaginitis
Therapeutics by Type - Prescription (Rx) and Over-the-Counter
(OTC) - Independent Analysis of Annual Sales in US$ Million for
the Years 2020 through 2027 and % CAGR
Table 140: Argentina Historic Review for Vaginitis Therapeutics
by Type - Prescription (Rx) and Over-the-Counter (OTC) Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 141: Argentina 15-Year Perspective for Vaginitis
Therapeutics by Type - Percentage Breakdown of Value Sales for
Prescription (Rx) and Over-the-Counter (OTC) for the Years
2012, 2020 & 2027
BRAZIL
Table 142: Brazil Current & Future Analysis for Vaginitis
Therapeutics by Product - Anti-Bacterial, Anti-Fungal and
Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p06033213/?utm_source=GNW
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________